Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 337 followers
Latest posts
Last updated about 2 hours ago
‘We have what we need to grow:’ Biogen CEO happy to ease off the M&A for a while
about 2 hours ago
Biogen's business development team may have been busy in recent years, but...
Novo Nordisk fails to dismiss lawsuit over CagriSema readout
about 3 hours ago
Novo Nordisk’s attempt to dismiss a lawsuit about its CagriSema readout has...
Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ Rhapsido
about 3 hours ago
Processa Pharmaceuticals has made a push into the autoimmune space via the...
‘Reverse mergers are increasingly popular’: Caldera hops on Synlogic’s Nasdaq listing
about 3 hours ago
Caldera Therapeutics has struck a reverse merger with the publicly traded Synlogic...
Vertex’s latest autoimmune TCE play involves $28M upfront to AbCellera
about 5 hours ago
AbCellera’s T-cell engager platform has reeled in a second client this summer...
Eli Lilly tops new biopharma ranking on launch success, development speed
about 22 hours ago
Flush with GLP-1 cash and pipeline success, Eli Lilly rose from 16th...
Acrosian debuts as AI-focused biometrics CRO
about 23 hours ago
The founders of contract research organization Quartesian have reunited to form Acrosian...
Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen options
1 day ago
Incyte has ditched a JAK2 inhibitor in phase 1 development for a...
Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder win
1 day ago
An experimental drug targeting both GLP-1 and glucagon receptors has curbed heavy...
GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
1 day ago
GSK has unveiled an ambitious three-year plan to divert resources to its...
Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trial
1 day ago
Atea Pharmaceuticals’ hepatitis C prospect has matched Gilead’s Epclusa in a phase...
Guardant Health taps Patrick Dempsey for emotional colorectal cancer awareness video
1 day ago
Colorectal cancer blood test maker Guardant Health has teamed up with “Grey’s...